A major step forward in regional collaboration for cancer care was announced today with the launch of Project ACTIVE 2.0 ...
A research team led by the Department of Clinical Oncology, Center of Cancer Medicine, School of Clinical Medicine, LKS ...
The Phase 1a clinical trial began with dose escalation of BTX-9341 as a monotherapy, followed by a combination with fulvestrant. The primary objective of the Phase 1a trial is to assess safety, ...
Accession Therapeutics doses first patient in phase 1 trial of TROCEPT-01, a novel cancer immunotherapy: Oxford, UK Tuesday, November 18, 2025, 13:00 Hrs [IST] Accession Therapeut ...
Fred Hutch bioengineer Dr. Matthias Stephan is working to develop a special foam that could help make gene therapy for blood ...
Accession Therapeutics Limited, a biopharmaceutical company developing next generation cancer immunotherapies, today announced it has dosed the first patient in its Phase I clinical trial evaluating ...
Two U.S. Food and Drug Administration (FDA)-approved drugs for treating prostate cancer may also be effective against acute myeloid leukemia (AML), according to a new study by researchers at Penn ...
Community Health System and Valley Children’s Healthcare are leading the charge in Central Valley cancer treatment, bringing advanced cellular and gene therapies — including CAR-T therapy — closer to ...
The Princess of Wales delivers her first public speech in over two years since her cancer diagnosis, urging greater value on ...
AI breakthroughs in pharma are pushing Eli Lilly and healthcare stocks higher—and may soon reshape how we fight cancer.
Ground-breaking breast cancer imaging research from the North East has been internationally showcased, with the latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback